Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Second Line Advanced Transitional Cell Carcinoma
NCT00792025Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Dec 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in transitional cell carcinoma (TCC), sponsored by Institut Curie. Primary endpoint: Objective Response Rate. Started Dec 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT00792025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792025.